Front Desk: 469-391-0070
Ipilimumab Treatment: Uses, Dosage, and Side Effects Explained
Summary of Key Points
Ipilimumab is an immunotherapy used to treat several types of cancer, including melanoma, lung cancer, and kidney cancer. It works by enhancing the immune system’s ability to recognize and attack cancer cells. Ipilimumab is administered through an intravenous (IV) infusion, typically in a healthcare setting. Like all medications, it may cause side effects, so it’s important to discuss your treatment plan with your healthcare provider.
Names of Medication
US Brand Name: Yervoy
Generic Name: Ipilimumab
The generic name refers to the active ingredient, while the brand name is assigned by the manufacturer. In this article, the generic name is listed in parentheses.
Pharmacologic Category
Immune Checkpoint Inhibitor
Anti-CTLA-4 Monoclonal Antibody
Ipilimumab Dosage
Ipilimumab is prescribed for various cancers, with the dosage and frequency tailored to the specific condition being treated. Always consult your healthcare provider before making any changes to your treatment plan. You can also schedule a telemedicine appointment with one of our providers for personalized advice.
Ipilimumab for Melanoma
Dosage: 3 mg/kg IV every 3 weeks for 4 doses.
Ipilimumab for Non-Small Cell Lung Cancer
Dosage: 1 mg/kg IV every 6 weeks in combination with other medications.
Ipilimumab for Renal Cell Carcinoma (Kidney Cancer)
Dosage: 1 mg/kg IV every 3 weeks for 4 doses, combined with another medication, followed by maintenance therapy.
Ipilimumab for Colorectal Cancer
Dosage: 3 mg/kg IV every 3 weeks for 4 doses, combined with other medications.
Ipilimumab for Hodgkin Lymphoma
Dosage: 3 mg/kg IV every 3 weeks for 4 doses.
Ipilimumab for Head and Neck Cancer
Dosage: 3 mg/kg IV every 3 weeks for 4 doses, combined with other medications.
Ipilimumab for Bladder Cancer
Dosage: 1 mg/kg IV every 6 weeks, combined with other medications.
Ipilimumab for Liver Cancer
Dosage: 3 mg/kg IV every 3 weeks for 4 doses, combined with other medications.
Ipilimumab for Esophageal Cancer
Dosage: 3 mg/kg IV every 3 weeks for 4 doses, combined with other medications.
Ipilimumab for Pancreatic Cancer
Dosage: 3 mg/kg IV every 3 weeks for 4 doses, combined with other medications.
Dosage Forms and Strengths
Injection: 50 mg/10 mL (5 mg/mL)
Injection: 200 mg/40 mL (5 mg/mL)
Administration Instructions for Ipilimumab
Ipilimumab is given as an intravenous (IV) infusion, meaning it is delivered directly into a vein. The infusion typically takes about 90 minutes. This treatment is administered in a healthcare setting, such as a hospital or clinic, where a healthcare professional will monitor you during and after the infusion for any side effects or reactions. It’s important to follow your healthcare provider’s instructions regarding the timing and frequency of your treatments.
Contraindications for Ipilimumab Treatment
A contraindication is a condition or situation where a specific treatment or medication should not be used because it may be harmful. It’s crucial to be aware of any contraindications before starting Ipilimumab.
Severe autoimmune diseases: If you have an autoimmune condition such as lupus, rheumatoid arthritis, or inflammatory bowel disease, Ipilimumab may worsen your symptoms. This is because Ipilimumab stimulates the immune system, which could cause it to attack healthy tissues.
History of severe immune-related reactions: If you’ve experienced severe immune-related side effects from immunotherapy, you may be at higher risk of similar or more severe reactions with Ipilimumab.
Organ transplant recipients: Ipilimumab can increase the risk of organ rejection in transplant patients. The medication stimulates the immune system, which may cause it to attack the transplanted organ.
Severe liver disease: Ipilimumab can cause liver inflammation (hepatitis), and if you already have liver disease, this could lead to serious complications.
Pregnancy: Ipilimumab is not recommended during pregnancy due to the potential risk to the developing fetus (discussed in more detail below).
If you have any of these conditions, consult your healthcare provider before starting Ipilimumab. Our telemedicine providers are available to review your medical history and help you make the best decision for your health.
Drug-to-Drug Interactions with Ipilimumab
Ipilimumab may interact with other medications, increasing the risk of side effects or reducing its effectiveness. Be sure to inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter medications, and supplements. Some medications that may interact with Ipilimumab include:
Corticosteroids (e.g., Prednisone): These drugs suppress the immune system and may reduce Ipilimumab’s effectiveness.
Immunosuppressants (e.g., Azathioprine, Cyclosporine): These medications also suppress the immune system, potentially counteracting Ipilimumab’s immune-boosting effects.
Anti-TNF agents (e.g., Infliximab, brand name Remicade): Used to treat autoimmune diseases, these drugs may increase the risk of immune-related side effects when combined with Ipilimumab.
If you are taking any of these medications, consult your healthcare provider to determine if Ipilimumab is appropriate for you. You can schedule a telemedicine appointment with one of our providers to discuss your medications and treatment options.
Ipilimumab in Pregnancy
Is it safe to take Ipilimumab when pregnant?
Ipilimumab is generally not recommended during pregnancy. Animal studies suggest it may harm the developing fetus, and there is limited information on its effects in pregnant women. Since Ipilimumab works by stimulating the immune system, it could potentially lead to complications during pregnancy, including risks to the fetus. If you are pregnant or planning to become pregnant, it’s important to discuss alternative treatment options with your healthcare provider. Our telemedicine providers are also available to help you make informed decisions about cancer treatment during pregnancy.
Ipilimumab while Breastfeeding
Is it safe to take Ipilimumab while breastfeeding?
It is not yet known whether Ipilimumab passes into breast milk. Due to the potential for serious side effects in a nursing infant, breastfeeding is not recommended while undergoing treatment with Ipilimumab. If you are currently breastfeeding or planning to breastfeed, it’s essential to talk with your healthcare provider about the risks and benefits of continuing treatment. You can also consult one of our telemedicine providers to explore your options.
Estimated Cost of Ipilimumab Treatment
The cost of Ipilimumab can vary depending on your location and insurance coverage. Without insurance, the estimated cost for a 30-day supply using a GoodRx coupon ranges from $150,000 to $200,000. It’s important to check with your insurance provider to confirm coverage, as many plans include cancer treatments like Ipilimumab.
Possible Alternatives to Ipilimumab
Depending on the type of cancer you have, there may be alternative treatments or lifestyle changes that could be considered. Always consult your healthcare provider before making any changes to your treatment plan. Our telemedicine providers are available to help guide you through your options.
Melanoma
Alternatives include other immunotherapies such as Pembrolizumab (Keytruda) or Nivolumab (Opdivo). For some patients, targeted therapies like BRAF inhibitors may also be appropriate. In addition, practicing sun protection and scheduling regular skin checks are essential lifestyle adjustments.
Non-Small Cell Lung Cancer
Alternatives may include chemotherapy, radiation therapy, or targeted therapies like Erlotinib (Tarceva) for patients with specific genetic mutations.
Renal Cell Carcinoma
Targeted therapies such as Sunitinib (Sutent) or Pazopanib (Votrient) may be considered as alternatives. Maintaining a balanced diet and staying physically active can also support your overall health.
Colorectal Cancer
Chemotherapy, radiation therapy, and targeted therapies like Bevacizumab (Avastin) are potential alternatives. A high-fiber diet and regular exercise can help manage symptoms and improve overall well-being.
Hodgkin Lymphoma
Chemotherapy and radiation therapy are common alternatives. Additionally, maintaining a healthy lifestyle and managing stress can support your treatment and recovery.
Head and Neck Cancer
Alternatives may include surgery, radiation therapy, and chemotherapy. Avoiding tobacco and alcohol can also help reduce the risk of recurrence.
Bladder Cancer
Alternatives include chemotherapy, radiation therapy, and surgery. Staying hydrated and avoiding smoking can support bladder health and overall recovery.
Liver Cancer
Targeted therapies such as Sorafenib (Nexavar) or Lenvatinib (Lenvima) may be considered. Maintaining a healthy weight and avoiding alcohol can help protect liver function and improve outcomes.
Esophageal Cancer
Chemotherapy, radiation therapy, and surgery are common alternatives. Eating smaller, more frequent meals and avoiding spicy or acidic foods can help manage symptoms and improve comfort.
Pancreatic Cancer
Alternatives include chemotherapy, radiation therapy, and surgery. Maintaining a healthy diet and managing blood sugar levels can support your overall health during treatment.
Recent Updates on Ipilimumab Research
Recent studies have explored combining Ipilimumab with other immunotherapies to improve outcomes for patients with advanced cancers. For example, combining Ipilimumab with Nivolumab (Opdivo) has shown promising results in treating melanoma, renal cell carcinoma, and non-small cell lung cancer. Ongoing clinical trials are also investigating the use of Ipilimumab in combination with targeted therapies and chemotherapy for various cancers.
Researchers are also working to reduce immune-related side effects while maintaining Ipilimumab’s effectiveness. This includes studying biomarkers that may help predict which patients are most likely to benefit from the treatment. If you are interested in learning more about ongoing clinical trials or new treatment options, our telemedicine providers can guide you through the latest research and its potential impact on your care.
